Beyond RSWA in prodromal α-synuclein disease: Do periodic limb movements signal potential early dopaminergic dysfunction?

Sleep MedJun 13, 2026 (epub)
Case ReportNeurology

Sasikanth Gorantla, Matteo Cesari, Raffaele Ferri

✦ AI-curated · Sources linked

Case in brief

This report describes two individuals with positive SYNONE skin biopsies for phosphorylated α-synuclein, who presented without REM sleep without atonia (RSWA) but exhibited significantly elevated periodic limb movement indices (PLMI >100) and mild restless legs syndrome. A third patient with a PLMI of 84 tested negative for SYNONE. These findings suggest a potential early indicator of dopaminergic dysfunction.

What made this case unusual

The combination of SYNONE positivity and RSWA negativity in these patients is noteworthy, as such presentations have not been previously reported.

Diagnostic / clinical pearl

Clinicians should consider the possibility of early dopaminergic dysfunction in patients with elevated periodic limb movements, even in the absence of typical REM sleep behavior disorder.

Why it matters

Understanding these atypical presentations may enhance early detection of α-synucleinopathies and inform future diagnostic criteria.

Source

Published in Sleep Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.